• PDF: Delivered by email within 12 to 24 hours of placing the order (Mon-Fri)

Healthcare-Acquired Infection
Devices, Pharmaceuticals, and Environmental Products

  • Publication Date:August 2011
  • Publisher:BCC Research
  • Product Type: Report
  • Pages:201

Healthcare-Acquired Infection Devices, Pharmaceuticals, and Environmental Products

REPORT HIGHLIGHTS

  • The global market for healthcare-acquired infection treatments were $16 billion in year 2010. This market is estimated to be around $19 billion in the year 2011 and is forecasted to cross $30 billion by 2016 at a CAGR of 9.5% for five year period.
  • Markets for infection control devices and products were $8.3 billion in the year 2010 and are expected to reach $10.3 billion by 2011. This market is forecasted to cross $18.3 billion by 2016 at a CAGR of 12%.
  • The market for pharmaceutical treatments is expected to be around $4.5 billion. This market is expected to increase at a 5.8% compound annual growth rate (CAGR) to reach $6 billion by 2016.

REPORT SCOPE

INTRODUCTION

REASONS FOR DOING THE STUDY

The objective of this study is to provide an in-depth analysis and forecast of the selected areas of the global healthcare-acquired infection (HAI) market. HAI is sometimes used to mean hospital-acquired infections, but for purposes of this report, HAI includes hospitals, nursing homes, outpatient surgery centers, and dialysis centers. Another term for healthcare-acquired infections is nosocomial infections.

The focus of this report is on devices, pharmaceuticals, and therapies currently used or under development for treatment of viral, bacterial, or fungal infections.

The global market for HAI products is estimated at between $10 billion and $15 billion in 2010, depending on the products included in the study, with high single-digit growth through 2016. Although the U.S. holds between 45% and 50% of the market, the fastest-growing regions for HAI treatments are the Asia-Pacific, which includes China, and Brazil.

STUDY GOALS AND OBJECTIVES

Healthcare-acquired infections are viral, bacterial, or fungal infections that patients acquire after they are admitted to a healthcare facility. Patients can acquire these infections from routine care; surgery; or as a complication from the use of medical devices such as ventilators, catheters, and intravenous lines.

The Centers for Disease Control (CDC) estimates that 2 million HAIs occur annually in the U.S. This leads to 100,000 deaths and costs an additional $36 billion to $45 billion in direct medical costs annually.

This report is designed to investigate the global HAI market by treatment area and by treatment type, with supporting tables and figures to illustrate projected growth. The report will include the U.S., Europe, Japan, and other countries such as China.

This report offers forecasts of the markets for devices, pharmaceuticals, and therapies by treatment segment and treatment type from 2011 through 2016, including supporting analyses for projections.

This report is a valuable tool for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in this market. It provides background on the structure of the HAI market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.

This is an invaluable tool for business planners; acquisition specialists; licensing strategists; product managers; market research analysts; investing consultants; and others interested in the HAI market, its products, its participants, and its future.

METHODOLOGIES AND INFORMATION SOURCES

Information for this report was obtained from various primary and secondary research sources, including industry analysts, annual reports, Securities and Exchange Commission (SEC) reports, the World Health Organization (WHO), the National Institutes of Health (NIH), American Hospital Association (AHA), Infectious Disease Society of America (IDSA), American Society of Heating, Refrigerating and Air Conditioning Engineers (ASHRAE), National Institute of Allergy and Infectious Diseases (NIAID), the National Hospital Discharge Survey (NHDS), government agencies outside the U.S, and journal articles. Secondary sources include literature searches, product literature, and press releases.

When precise information was unavailable, a consensus is made using reasonable assumptions and estimates based on historical data.

  • CHAPTER ONE: INTRODUCTION
    • REASONS FOR DOING THE STUDY
    • STUDY GOALS AND OBJECTIVES
    • METHODOLOGIES AND INFORMATION SOURCES
    • ANALYST CREDENTIALS
    • RELATED BCC REPORTS
    • BCC ONLINE SERVICES
    • DISCLAIMER
  • CHAPTER TWO: SUMMARY
    • SUMMARY (CONTINUED)
    • SUMMARY TABLE GLOBAL MARKET FOR HAI TREATMENTS, THROUGH 2016 ($ MILLIONS)
    • SUMMARY FIGURE GLOBAL MARKET FOR HAI TREATMENTS BY GEOGRAPHICAL AREA, 2010 AND 2016 (%)
  • CHAPTER THREE: OVERVIEW
    • TABLE 1 GLOBAL PREVALENCE OF HEALTHCARE-ACQUIRED INFECTIONS (PER 100 PATIENTS)
    • TABLE 1 (CONTINUED)
    • IMPORTANCE OF HAND WASHING
    • MOST COMMON HEALTHCARE-ASSOCIATED INFECTIONS
    • TABLE 2 CAUSES AND TYPES OF HEALTHCARE-ACQUIRED INFECTIONS
    • TABLE 2 (CONTINUED)
    • GRAM-POSITIVE BACTERIA
    • S. AUREUS
    • Transmission Routes
    • MRSA
    • Rate of Infection
    • Transmission Routes
    • TYPES OF PNEUMONIA
    • Pseudomonas Aeruginosa
    • Hospital-Acquired Pneumonia
    • Klebsiella Pneumonia
    • CLOSTRIDIUM DIFFICILE
    • MYCOBACTERIUM TUBERCULOSIS
    • Scope of Infection
    • E. COLI
    • UTI Treatment Options
    • GASTROENTERITIS-CAUSING BACTERIA
    • Treatment Options
    • VANCOMYCIN-RESISTANT ENTEROCOCCI
    • Types of VRE
    • LEGIONELLA BACTERIA
    • Treatment Options
    • GRAM-NEGATIVE BACTERIA
    • PSEUDOMONAS AERUGINOSA
    • ACINETOBACTER BAUMANNII
    • STENOTROPHOMONAS MALTOPHILIA
    • VIRAL INFECTIONS
    • VIRAL INFECTION RESEARCH
    • HEPATITIS B AND C
    • Scope of Infection
    • Treatment
    • HIV
    • Treatment
    • NOROVIRUS
    • INFLUENZA VIRUS
    • Influenzavirus A, B, C
    • Transmission
    • Symptoms
    • Treatment
    • RESPIRATORY SYNCYTIAL VIRUS
    • Treatment
    • FUNGAL INFECTIONS
    • ASPERGILLUS INFECTIONS
    • Treatment
    • YEAST INFECTIONS
    • Candida Infections
    • PREVENTING HAI
    • DETERMINING THE MODE OF TRANSMISSION
    • CDC RECOMMENDATIONS FOR PREVENTION
    • TABLE 3 CDC MEASURES FOR PREVENTION OF HEALTHCARE-ACQUIRED INFECTIONS, 2007
    • TABLE 3 (CONTINUED)
    • ROLES OF HEALTHCARE INSTITUTIONS AND INFECTION CONTROL INDIVIDUALS
    • TABLE 4 SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAM MEMBERS
    • TABLE 4 (CONTINUED)
    • COMPONENTS OF A HAI SURVEILLANCE SYSTEM
    • TABLE 5 MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVE INFECTION-CONTROL SURVEILLANCE SYSTEM
    • SUITABLE SURVEYS IN DEVELOPING COUNTRIES
    • HEALTHCARE INFECTION POINTS OF GENERATION
    • HOSPITALS
    • SURGICAL PROCEDURES
    • AMBULATORY SURGERY CENTERS IN THE U.S
    • Number of Procedures in ASCs
    • Infection Control in ASCs
    • DIALYSIS CENTERS
    • U.S. Dialysis Centers
    • Transmission of VRE
    • Hepatitis Transmission in U.S. Dialysis Centers
    • Hepatitis Transmission in Dialysis Centers Outside the U.S.
    • ASSISTED LIVING AND LONG-TERM CARE FACILITIES
    • TREATMENTS
    • PROACTIVE MEASURES
    • Environmental Controls
    • Device Design
    • REACTIVE MEASURES
    • CHANGES IN THE INDUSTRY
    • TABLE 6 SELECTED MERGERS AND/OR ACQUISITIONS, 2005-2011 ($ MILLIONS)
  • CHAPTER FOUR: GLOBAL HEALTHCARE-ACQUIRED INFECTION MARKET
    • U.S. MARKET
    • U.S. HEALTHCARE SPENDING
    • SCOPE OF HEALTHCARE-ACQUIRED INFECTIONS IN U.S.
    • Ventilator-Associated Pneumonia
    • RATE OF INFECTION
    • Intensive Care Units
    • Surgical Site Infections
    • Fungal Infections
    • COSTS
    • U.S. PREVENTION ACTION PLAN
    • TABLE 7 HHS ACTION PLAN FOR HAI PREVENTION (% REDUCTION)
    • EUROPEAN MARKET
    • SCOPE
    • HELICS
    • RATE OF INFECTION AND COSTS
    • JAPANESE MARKET
    • SCOPE
    • RATE OF INFECTION
    • CHINESE MARKET
    • SCOPE
    • RATE OF INFECTION
    • REST OF THE WORLD MARKET
    • SCOPE
    • RATE OF INFECTION
    • Rate of Infection (Continued)
    • OPPORTUNITIES AND CHALLENGES FOR HAI INDUSTRY
    • MEDICAL DEVICE OPPORTUNITIES AND CHALLENGES
    • Challenges
    • ENVIRONMENTAL AND STRUCTURAL OPPORTUNITIES AND CHALLENGES
    • Challenges
    • NEW TREATMENTS
    • PHARMACEUTICAL MARKET OPPORTUNITIES AND CHALLENGES
    • Patent Expiry
    • TABLE 8 SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS, 2005-2020
    • Pipeline Limitations
    • Global Recession
    • Regulatory Restrictions
    • Generic Competition
    • IMPACT OF DEMOGRAPHIC CHANGES
    • DEMOGRAPHIC CHANGES IN THE U.S
    • DEMOGRAPHIC CHANGES OUTSIDE THE U.S.
    • Demographic Changes Outside the U.S. (Continued)
  • CHAPTER FIVE: HAI PHARMACEUTICAL MARKET
    • GLOBAL MARKETS
    • ROLE OF EMERGING NATIONS
    • PHARMACEUTICALS USED FOR HEALTHCARE-ACQUIRED INFECTIONS
    • TABLE 9 GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE, THROUGH 2016 ($ MILLIONS)
    • GLOBAL GROWTH RATES FOR PHARMACEUTICALS
    • TABLE 10 ESTIMATED GROWTH OF PHARMACEUTICAL HEALTHCARE SPENDING BY REGION, THROUGH 2016 (%)
    • VIRAL HAI PHARMACEUTICALS
    • TABLE 11 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION, AND MANUFACTURER, 2010
    • FIGURE 1 ESTIMATED GLOBAL MARKET SHARE FOR PRESCRIPTION PHARMACEUTICALS TO TREAT VIRAL HAI BY COMPANY, 2010 (%)
    • FIGURE 2 GLOBAL MARKET FOR VIRAL BY DISEASE TYPE(%)
    • VIRAL PHARMACEUTICAL MARKET BY CONDITION
    • TABLE 12 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL HAI BY CONDITION, THROUGH 2016 ($ MILLIONS)
    • BACTERIAL HAI PHARMACEUTICALS
    • TABLE 13 SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME, INDICATION, AND MANUFACTURER, 2010
    • TABLE 13 (CONTINUED)
    • DRUG CLASSES
    • Aminoglycosides
    • B-Lactam Antibiotics
    • Cephalosporins
    • Glycopeptides
    • Lincosamides
    • Lipopeptides
    • Carbapenems
    • Penicillins
    • Polypeptides
    • Macrolides
    • Quinolones
    • Tetracyclines
    • Tuberculosis
    • Sulfonamides
    • Other Formulations
    • FIGURE 3 GLOBAL MARKET SHARE FOR PRESCRIPTION PHARMACEUTICALS TO TREAT BACTERIAL HAI BY COMPANY, 2010 (%)
    • TABLE 14 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT BACTERIAL HAI, THROUGH 2016 ($ MILLIONS)
    • TABLE 15 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT BACTERIAL HAI BY CONDITION, THROUGH 2016 ($ MILLIONS)
    • FUNGAL HAI PHARMACEUTICALS
    • TABLE 16 SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL INFECTIONS BY NAME, TYPE, AND MANUFACTURER, 2010
    • TABLE 17 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI, THROUGH 2016 ($ MILLIONS)
    • FIGURE 4 MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI BY COMPANY, 2010 (%)
    • GLOBAL OPPORTUNITIES
  • CHAPTER SIX: HAI ENVIRONMENTAL TREATMENT MARKET
    • GLOBAL HAI ENVIRONMENTAL TREATMENT MARKET
    • TABLE 18 GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 ($ MILLIONS)
    • PLANNING FOR CONSTRUCTION OR RENOVATION: U.S
    • Plans Involving Infection Control
    • AIR TREATMENT
    • ROOM FILTRATION SYSTEMS
    • ROOM PRESSURIZATION
    • HYDROGEN PEROXIDE VAPOR
    • Dedicated Airborne Isolation Rooms
    • WATER TREATMENT
    • DESIGN OF SINKS AND OTHER WATER FACILITIES
    • CLEANING PHYSICAL SURFACES
    • DISINFECTION
    • Advantages and Disadvantages of Disinfectants
    • TABLE 19 ADVANTAGES AND DISADVANTAGES OF COMMONLY USED DISINFECTANTS
    • TABLE 19 (CONTINUED)
    • PHENOLICS
    • OXIDIZING AGENTS
    • HALOGENS
    • ALDEHYDES
    • QUATERNARY AMINES
    • ALCOHOLS
    • TABLE 20 GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 ($ MILLIONS)
    • FIGURE 5 GLOBAL MARKET FOR DISINFECTANT PRODUCTS BY TYPE, 2010 (%)
    • FIGURE 5 (CONTINUED)
    • PATIENT SKIN PREPARATION DISINFECTANTS
    • IODINE
    • POVIDONE-IODINE SOLUTIONS
    • CHLORHEXIDINE GLUCONATE
    • TABLE 21 GLOBAL MARKET FOR PATIENT PREPARATION DISINFECTANTS, THROUGH 2016 ($ MILLIONS)
    • STERILIZATION SYSTEMS FOR INFECTION CONTROL
    • TABLE 22 GLOBAL MARKET FOR STERILIZATION DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 ($ MILLIONS)
    • CHEMICAL STERILIZATION
    • ETO Sterilization
    • Major Players in Chemical Sterilization
    • OTHER CHEMICAL STERILIZATION
    • Peracetic Acid
    • Hydrogen Peroxide
    • Chlorine Dioxide
    • Ozone
    • STEAM STERILIZATION
    • TABLE 23 SELECTED PLASTIC MATERIALS THAT RESPOND WELL TO STEAM STERILIZATION
    • Autoclaving
    • Major Players in Heat Sterilization
  • CHAPTER SEVEN: HAI MEDICAL DEVICES: CATHETERS, PATIENT VENTILATION SYSTEMS, AND IN-LINE STERILIZATION FILTERS
    • SELECTED GLOBAL MEDICAL HAI DEVICE MARKET
    • TABLE 24 GLOBAL MARKET FOR MEDICAL DEVICES THAT MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 ($ MILLIONS)
    • CATHETERS
    • USE OF COATINGS
    • CATHETER COATINGS
    • TABLE 25 SELECTED CATHETER PRODUCTS WITH ANTIBIOTIC PROPERTIES
    • Silver Coating
    • SURFACE-MODIFIED CATHETER
    • TABLE 26 GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIAL PROPERTIES, THROUGH 2016 ($ MILLIONS)
    • FIGURE 6 HAI CATHETER MARKET SHARES BY URINARY, CVC, PICC, AND OTHER SEGMENTS, 2011 AND 2016 (%)
    • FIGURE 6 (CONTINUED)
    • URINARY TRACT CATHETERS
    • CENTRAL VENOUS CATHETERS
    • Dialysis Catheters
    • Catheter-Related Bloodstream Infections
    • Catheter-Related Bloodstream Infections (Continued)
    • TABLE 27 POTENTIAL SOURCES OF CRBSI
    • PERIPHERALLY INSERTED CENTRAL VENOUS CATHETERS
    • MARKET OPPORTUNITIES FOR CATHETER MANUFACTURERS
    • CATHETER GROWTH IN REGIONAL MARKETS
    • TABLE 28 GLOBAL HAI CATHETER MARKET BY REGION, THROUGH 2016 ($ MILLIONS)
    • FIGURE 7 GLOBAL HAI CATHETER MARKET BY REGION, 2011 AND 2016 (%)
    • PATIENT VENTILATION DEVICES
    • TABLE 29 GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS, THROUGH 2016 ($ MILLIONS)
    • TYPES OF VENTILATION DEVICES
    • Non-Invasive Ventilators
    • TABLE 30 GLOBAL MARKET FOR NON-INVASIVE VENTILATIONS SYSTEMS FOR USE WITH PATIENTS WHO HAVE HAIS, THROUGH 2016 ($ MILLIONS)
    • ENDOTRACHEAL TUBES AND VENTILATION SYSTEMS
    • Coated Endotracheal Tubes
    • Tapered Endotracheal Tubes
    • TABLE 31 GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES DESIGNED TO MINIMIZE VAP, THROUGH 2016 ($ MILLIONS)
    • IN-LINE STERILE IV FILTRATION
    • TABLE 32 GLOBAL STERILE IV FILTER MARKET, THROUGH 2016 ($ MILLIONS)
  • CHAPTER EIGHT: REGULATIONS AND PATENTS
    • U.S. INFECTION CONTROL PROGRAMS
    • INFECTION CONTROL MEASURES AND PROTOCOLS
    • U.S. REGULATIONS
    • HOSPITAL INFECTIONS DISCLOSURE ACT
    • CURRENT AND PENDING REQUIREMENTS
    • Affordable Care Act and Implications for the Pharmaceutical Industry
    • Biosimilars
    • CMS Reimbursement for HAIs
    • EUROPEAN REGULATIONS
    • IMPLICATIONS FOR PHARMACEUTICAL MANUFACTURERS
    • JAPANESE REGULATIONS
    • CHINESE REGULATIONS
    • PATENTS
    • PATENTS BY MANUFACTURER
    • TABLE 33 PATENTS BY MANUFACTURER, 2005-2011
    • TABLE 33 (CONTINUED)
    • TABLE 33 (CONTINUED)
    • PATENTS BY DATE OF ISSUE
    • TABLE 34 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, 2005-2011
    • TABLE 34 (CONTINUED)
    • PATENTS BY MANUFACTURER
    • TABLE 35 PATENTS BY MANUFACTURER
    • TABLE 35 (CONTINUED)
    • PATENTS FOR DELIVERY OF PHARMACEUTICALS
    • TABLE 36 PATENT BY INDICATION: PHARMACEUTICAL DELIVERY, 2005-2011
    • BACTERIAL PHARMACEUTICAL PATENTS
    • TABLE 37 PATENTS BY INDICATION: BACTERIAL PHARMACEUTICAL, 2005-2011
    • TABLE 37 (CONTINUED)
    • TABLE 37 (CONTINUED)
    • TABLE 37 (CONTINUED)
    • FUNGAL PHARMACEUTICAL PATENTS
    • TABLE 38 PATENT BY INDICATION: FUNGAL PHARMACEUTICAL, 2010
    • VIRAL PHARMACEUTICAL PATENTS
    • TABLE 39 PATENTS BY INDICATION: VIRAL PHARMACEUTICAL, 2005-2011
    • TABLE 39 (CONTINUED)
    • TABLE 39 (CONTINUED)
    • ENVIRONMENTAL CONTROLS
    • TABLE 40 PATENT BY INDICATION: AIR FILTRATION, 2005-2011
    • TABLE 41 PATENTS BY INDICATION: WATER TREATMENT, 2005-2011
    • PATENTS FOR SURFACE DISINFECTANTS
    • TABLE 42 PATENTS BY INDICATION: DISINFECTANT SURFACES, 2005-2011
    • TABLE 42 (CONTINUED)
    • TABLE 42 (CONTINUED)
    • TABLE 43 PATENT BY INDICATION: SOLID WASTE TREATMENT, 2005-2011
    • PATENTS FOR DIAGNOSTIC PROCESSES
    • TABLE 44 PATENTS BY INDICATION: DIAGNOSTIC, 2006-2011
    • TABLE 44 (CONTINUED)
    • MEDICAL DEVICES
    • TABLE 45 PATENTS BY INDICATION: CATHETER, 2008-2011
    • TABLE 45 (CONTINUED)
    • TABLE 45 (CONTINUED)
    • TABLE 45 (CONTINUED)
    • TABLE 46 PATENTS BY INDICATION: ANTIMICROBIAL COATINGS, 2005-2011
    • TABLE 46 (CONTINUED)
    • TABLE 46 (CONTINUED)
    • TABLE 46 (CONTINUED)
    • TABLE 46 (CONTINUED)
    • TABLE 46 (CONTINUED)
  • CHAPTER NINE: CURRENT RESEARCH AND EMERGING THERAPIES
    • EMERGING RESEARCH
    • RAPID TESTING
    • ANTISEPTIC WASHES
    • PHARMACEUTICALS
    • MERCK
    • Boceprivir
    • VERTEX
    • Teleprivir
    • TIBOTEC
    • CEREXA
    • Ceftaroline
    • NXL104
    • BASILEA PHARMACEUTICALS
    • Ceftobiprole
    • Delafloxacin
    • JOHNSON & JOHNSON
    • Doribax
    • CUBIST PHARMACEUTICALS
    • CSA-201
    • CXA183,315
    • TOYAMA CHEMICAL
    • T-705
    • T-3912
    • T-2307
    • GLAXOSMITHKLINE
    • OPTIMER PHARMACEUTICALS
    • Fidaxomicin
    • AURICX
    • BPH-652
    • PFIZER
    • THE MEDICINES COMPANY
    • Oritavancin
    • STERILIZATION AND DISINFECTION
    • SHARKLET TECHNOLOGIES
    • HEALTHCARE FACILITY DESIGN
    • MEDICAL DEVICE DESIGN
    • ONDINE BIOMEDICAL
    • CERAGENIX PHARMACEUTICALS, INC.
    • RENAL SEPSIS MICROFILTER
  • CHAPTER TEN: COMPANY PROFILES
    • PHARMACEUTICALS
    • ABBOTT LABORATORIES
    • Business Overview
    • Financials
    • Products
    • ASTELLAS PHARMA, INC
    • Business Overview
    • Financial Information
    • Products
    • ASTRA TECH
    • ASTRAZENECA, PLC
    • Business Overview
    • Financials
    • Products
    • BACTIGUARD, AB
    • Business Overview
    • Financials
    • Products
    • BASILEA PHARMACEUTICA, LTD.
    • Business Overview
    • Financials
    • Products
    • BAYER, AG (MILES-BAYER)
    • Business Overview
    • Financials
    • Products
    • BOEHRINGER INGELHEIM, GMBH
    • Business Overview
    • Financials
    • Products
    • BRISTOL-MYERS SQUIBB
    • Business Overview
    • Financials
    • Products
    • CEREXA, INC. (FOREST LABORATORIES)
    • Business Overview
    • Financials
    • Products
    • CUBIST PHARMACEUTICALS
    • Business Overview
    • Financials
    • Products
    • ELAN CORPORATION
    • Business Overview
    • Financials
    • Products
    • FOREST LABORATORIES
    • Business Overview
    • Financials
    • Products
    • ELI LILLY AND COMPANY
    • Business Overview
    • Financials
    • Products
    • GILEAD SCIENCES
    • Business Overview
    • Financials
    • Products
    • GLAXOSMITHKLINE
    • Business Overview
    • Financials
    • Products
    • JOHNSON & JOHNSON
    • Business Overview
    • Financial Information
    • Products
    • MEDIMMUNE PHARMACEUTICALS
    • Business Overview
    • Financials
    • Products
    • MERCK
    • Business Overview
    • Financials
    • Products
    • NABI BIOPHARMACEUTICALS
    • Business Overview
    • Financials
    • Products
    • PFIZER
    • Business Overview
    • Financials
    • Products
    • ROCHE PHARMACEUTICALS
    • Business Overview
    • Financials
    • Products
    • SANOFI AVENTIS
    • Business Overview
    • Financials
    • Products
    • SCHERING-PLOUGH
    • THE MEDICINES COMPANY
    • Business Overview
    • Financials
    • Products
    • THERAVANCE
    • Business Overview
    • Financials
    • Products
    • TOYAMA CHEMICAL CO, LTD
    • Business Overview
    • Financials
    • Products
    • VERTEX PHARMACEUTICALS, INC
    • Business Overview
    • Financials
    • Products
    • VIROPHARMA, INC.
    • Business Overview
    • Financials
    • Products
    • ENVIRONMENTAL PRODUCTS
    • 3M HEALTHCARE, MEDICAL DIVISION
    • Business Overview
    • Financials
    • Products
    • ADVANCED STERILIZATION PRODUCTS
    • Business Overview
    • Financials
    • Products
    • ANDERSEN PRODUCTS, INC
    • Business Overview
    • Financials
    • Products
    • BAXTER INTERNATIONAL
    • Business Overview
    • Financials
    • Products
    • DIVERSEY, INC
    • Business Overview
    • Financials
    • Products
    • ECOLAB
    • Business Overview
    • Financials
    • Products
    • GETINGE USA, INC.
    • Business Overview
    • Financials
    • Products
    • PRIMUS STERILIZER CO., INC.
    • Business Overview
    • Financials
    • Products
    • RUHOF CORP.
    • Business Overview
    • Financials
    • Products
    • STERIGENICS
    • Business Overview
    • Financials
    • Products
    • STERIS CORP.
    • Business Overview
    • Financials
    • Products
    • TUTTANAUER USA CO., LTD
    • Business Overview
    • Financials
    • Products
    • ULTRAVIOLET DEVICES, INC
    • Business Overview
    • Financials
    • Products
    • XENEX HEALTHCARE SERVICES
    • Business Overview
    • Financials
    • Products
    • INFECTION CONTROL DEVICES
    • B. BRAUN MELSUNGEN, AG
    • Business Overview
    • Financials
    • Products
    • BECTON DICKINSON
    • Business Overview
    • Financials
    • Products
    • BIOMÉRIEUX, INC
    • Business Overview
    • Financials
    • Products
    • CANTEL MEDICAL CORP
    • Business Overview
    • Financials
    • Products
    • CAREFUSION CORP.
    • Business Overview
    • Financials
    • Products
    • CEPHEID
    • Business Overview
    • Financials
    • Products
    • CLOROX CO
    • Business Overview
    • Financials
    • Products
    • COLOPLAST GROUP
    • Business Overview
    • Financials
    • Products
    • CONVATEC
    • Business Overview
    • Financial
    • Products
    • COOK MEDICAL
    • Business Overview
    • Financials
    • Products
    • COVIDIEN, PLC
    • Business Overview
    • Financials
    • Products
    • CR BARD
    • Business Overview
    • Financials
    • Products
    • DRAGER MEDICAL, LTD., U.K
    • Business Overview
    • Financials
    • Products
    • HOLLISTER, INC.
    • Business Overview
    • Financials
    • Products
    • KIMBERLY-CLARK HEALTHCARE
    • Business Overview
    • Financials
    • Products
    • ODINE BIOMEDICAL, INC.
    • Business Overview
    • Financials
    • Products
    • TELEFLEX MEDICAL
    • Business Overview
    • Financials
    • Products
    • WELCH ALLYN, INC.
    • Business Overview
    • Financials
    • Products
+44 20 8816 8548

Ask a question about Healthcare-Acquired Infection

Enter the characters you see in the picture below
Captcha